This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tobin, N. H.
Right arrow Articles by Frenkel, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tobin, N. H.
Right arrow Articles by Frenkel, L. M.

 Previous Article  |  Next Article 

Journal of Virology, August 2005, p. 9625-9634, Vol. 79, No. 15
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.15.9625-9634.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Evidence that Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of Virus

Nicole H. Tobin,1 Gerald H. Learn,2 Sarah E. Holte,3 Yang Wang,2,{dagger} Ann J. Melvin,1 Jennifer L. McKernan,1 Diane M. Pawluk,1,{ddagger} Kathleen M. Mohan,1 Paul F. Lewis,4 James I. Mullins,2,5,6 and Lisa M. Frenkel1,5*

Departments of Pediatrics,1 Microbiology,2 Biostatistics,3 Laboratory Medicine,5 Medicine, University of Washington, Seattle, Washington,6 Oregon Health Sciences University, Portland, Oregon4

Received 23 August 2004/ Accepted 19 April 2005

Episodes of low-level viremia (LLV), with plasma human immunodeficiency virus type 1 (HIV-1) RNA levels ranging from 50 to 400 copies (c)/ml, occur commonly during highly active antiretroviral therapy (HAART). LLV has been associated with virologic failure of HAART in some studies, while in others LLV did not appear to affect the clinical outcome. To understand the processes leading to LLV, genetic analyses were used to determine whether plasma virions emanated from archived or from newly evolved viral genomes. Episodes of LLV (plasma HIV-1 RNA, 50 to 379 [median, 77] c/ml) were detected in 21/37 (57%) HIV-1-infected children with median plasma HIV-1 RNA levels of <50 c/ml during 79 patient years of HAART. Viral sequences were derived by direct sequencing of PCR products from 21 plasma specimens diluted to end point. In phylogenetic analysis, LLV viral sequences grouped with virus from early in the course of infection in 8/11 subjects. Six specimens had multiple identical viral sequences, suggesting origin from clonally expanded infected cells. LLV plasma virus evolved over time, indicating viral replication, in 3/11 subjects. Two of these had frequent LLV, including the selection of drug-resistant mutants. In summary, plasma virus from episodes of LLV during effective HAART appeared to originate from two distinct processes, (i) clonal outgrowth from long-lived HIV-1-infected cells, presumably following activation and proliferation of these cells, and (ii) ongoing viral replication that included the selection of new drug-resistant mutants. These observations provide a plausible explanation for the divergent clinical outcomes previously associated with LLV.

* Corresponding author. Mailing address: 4800 Sand Point Way, NE CW, Seattle, WA 98105. Phone: (206) 987-5140. Fax: (206) 987-7311. E-mail: lfrenkel{at}u.washington.edu.

{dagger} Present address: Department of Biostatistics, University of Washington School of Medicine, Seattle, WA 98195-4806.

{ddagger} Present address: P.O. Box 416, Kirkland, WA 98083.

Journal of Virology, August 2005, p. 9625-9634, Vol. 79, No. 15
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.15.9625-9634.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Shiu, C., Cunningham, C. K., Greenough, T., Muresan, P., Sanchez-Merino, V., Carey, V., Jackson, J. B., Ziemniak, C., Fox, L., Belzer, M., Ray, S. C., Luzuriaga, K., Persaud, D., and the Pediatric AIDS Clinical Trials Group P1059, (2009). Identification of Ongoing Human Immunodeficiency Virus Type 1 (HIV-1) Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive Highly Active Antiretroviral Therapy. J. Virol. 83: 9731-9742 [Abstract] [Full Text]  
  • Dinoso, J. B., Rabi, S. A., Blankson, J. N., Gama, L., Mankowski, J. L., Siliciano, R. F., Zink, M. C., Clements, J. E. (2009). A Simian Immunodeficiency Virus-Infected Macaque Model To Study Viral Reservoirs That Persist during Highly Active Antiretroviral Therapy. J. Virol. 83: 9247-9257 [Abstract] [Full Text]  
  • Brennan, T. P., Woods, J. O., Sedaghat, A. R., Siliciano, J. D., Siliciano, R. F., Wilke, C. O. (2009). Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy. J. Virol. 83: 8470-8481 [Abstract] [Full Text]  
  • Bull, M. E., Learn, G. H., McElhone, S., Hitti, J., Lockhart, D., Holte, S., Dragavon, J., Coombs, R. W., Mullins, J. I., Frenkel, L. M. (2009). Monotypic Human Immunodeficiency Virus Type 1 Genotypes across the Uterine Cervix and in Blood Suggest Proliferation of Cells with Provirus. J. Virol. 83: 6020-6028 [Abstract] [Full Text]  
  • Eilers, M., Roy, U., Mondal, D. (2008). MRP (ABCC) Transporters-Mediated Efflux of Anti-HIV Drugs, Saquinavir and Zidovudine, from Human Endothelial Cells. Exp. Biol. Med. 233: 1149-1160 [Abstract] [Full Text]  
  • Ambrose, Z., Palmer, S., Boltz, V. F., Kearney, M., Larsen, K., Polacino, P., Flanary, L., Oswald, K., Piatak, M. Jr., Smedley, J., Shao, W., Bischofberger, N., Maldarelli, F., Kimata, J. T., Mellors, J. W., Hu, S.-L., Coffin, J. M., Lifson, J. D., KewalRamani, V. N. (2007). Suppression of Viremia and Evolution of Human Immunodeficiency Virus Type 1 Drug Resistance in a Macaque Model for Antiretroviral Therapy. J. Virol. 81: 12145-12155 [Abstract] [Full Text]  
  • Kaiser, P., Joos, B., Niederost, B., Weber, R., Gunthard, H. F., Fischer, M., the Swiss HIV Cohort Study, (2007). Productive Human Immunodeficiency Virus Type 1 Infection in Peripheral Blood Predominantly Takes Place in CD4/CD8 Double-Negative T Lymphocytes. J. Virol. 81: 9693-9706 [Abstract] [Full Text]  
  • Bailey, J. R., Sedaghat, A. R., Kieffer, T., Brennan, T., Lee, P. K., Wind-Rotolo, M., Haggerty, C. M., Kamireddi, A. R., Liu, Y., Lee, J., Persaud, D., Gallant, J. E., Cofrancesco, J. Jr., Quinn, T. C., Wilke, C. O., Ray, S. C., Siliciano, J. D., Nettles, R. E., Siliciano, R. F. (2006). Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells.. J. Virol. 80: 6441-6457 [Abstract] [Full Text]  
  • Bailey, J. R., Lassen, K. G., Yang, H.-C., Quinn, T. C., Ray, S. C., Blankson, J. N., Siliciano, R. F. (2006). Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.. J. Virol. 80: 4758-4770 [Abstract] [Full Text]  
  • Devadas, K., Dhawan, S. (2006). Hemin Activation Ameliorates HIV-1 Infection via Heme Oxygenase-1 Induction. J. Immunol. 176: 4252-4257 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»